GEN Exclusives

More »

GEN News Highlights

More »
Aug 2, 2007

Lonza Adds In Silico Protein Analysis Platform to Portfolio

  • Lonza acquired all assets relating to the AggreSolve™ Technology and Services business of Zyentia. This tool is for the selection and development of biopharmaceuticals.

    Lonza reports that this transaction is in line with the planned expansion and diversification of the technology toolbox within the Lonza Biopharmaceuticals Mammalian (LBM) R&D business unit.  The tool will be incorporated into LBM R&D, forming a new function entitled Advanced Protein Technologies. The site will consist of up to 186 square meters.

    The company says that AggreSolve will support its plan to incorporate “Quality by Design” directly at the molecular level with the overall aim of improving product quality, safety, and manufacturability. It is a comprehensive in silico protein analysis platform that screens proteins to predict aggregation problems as well as sequence changes likely to reduce aggregation and enhances the design of aggregation inhibitors and stabilizers.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »